Delivery Order SPE2DB24D3014-SPE2DB25FKUTB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Methylphenidate ER 54 mg tablets (100-count bottles) under a firm fixed-price contract with a ceiling value of $1,431.52. This is a non-set-aside competitive award, with an ultimate completion date of June 3, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a $1,978.18 delivery order by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Methylphenidate ER 27 mg tablets (100-count bottles). This firm fixed-price, competitively awarded contract is scheduled for completion by September 17, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a child delivery order under a larger contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Methylphenidate ER 54 mg tablets (100-count units) with a ceiling value of $1,533.28. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The ultimate completion date is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Methylphenidate ER 54 mg tablets (100-count) with a ceiling value of $3,055.44. This firm fixed-price delivery order, which is expected to be completed by September 4, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Methylphenidate ER 54 mg tablets (100-count units) with a ceiling value of $1,391.74. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs, particularly for military and veteran...
- AmerisourceBergen Drug Corp received a delivery order from the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Methylphenidate ER 36 mg tablets in quantities of 100 units, with a contract ceiling value of $3,523.73. The award, which is non-competitive and represents a child contract under a larger vehicle, is scheduled for completion by September 4, 2025. This delivery order operates under a firm fixed price structure and will be performed at the contractor's facility in...
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on August 1, 2025, for the supply of Methylphenidate ER 36 mg tablets in quantities of 100 units. The contract is valued at $1,541.16 with a firm fixed price structure and an ultimate completion date of August 4, 2025. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical prime vendor agreement...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for Methylphenidate ER 54 mg tablets (100-count) with a ceiling value of $1,183.83 and an ultimate completion date of September 2, 2025. This is a firm fixed-price, non-set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Methylphenidate ER 18 mg tablets in a quantity of 100 units, valued at $4,817.50. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide 100 units of methylphenidate ER 54 mg tablets. The contract has a potential value of $1,173.69 and a completion date of January 29, 2024. This delivery order is issued under an indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp as the prime contractor, with a potential value of $999,999,999.00 and a...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUTBDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 18, 2025, for the supply of Methylphenidate ER 54 mg tablets (100-count bottles) with a ceiling value of $1,827.84. This is a firm fixed-price contract with an ultimate completion date of September 19, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a competitive, non-set-aside procurement issued under DLA's existing contract vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp has demonstrated capability to fulfill federal requirements through open competition across a diverse portfolio of medications and medical commodities serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/18/25 |